Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<keyword id="19914246" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="keywords" meta.keywordsubtype="org" meta.entityname="Zydus Lifesciences" meta.hostid="261" meta.entityid="Zydus Lifesciences">Zydus Lifesciences</keyword> on Friday said its consolidated <keyword id="19942166" type="General" weightage="20" keywordseo="net-profit" source="keywords">net profit</keyword> surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal. <br /><br /> Revenue from operations rose to Rs 5,534 crore in the period under review from Rs 5,011 crore in the year-ago period, Zydus Lifesciences said in a statement. <br /><br /> For the year ended March 31, 2024, the company reported a consolidated net profit of Rs 3,859 crore as compared with Rs 1,960 crore in FY23. Revenue from operations rose to Rs 19,547 crore from Rs 17,237 crore in the 2022-23 fiscal. <br /><br /> "Our relentless focus on patient centricity, operational efficiency, strategic investments, and execution of our diversified product portfolio continues to pay off, resulting in a significant improvement in profitability as well," Zydus Lifesciences MD Sharvil Patel said. <br /><br /> The company said its board has approved a final dividend of Rs 3 per equity share of Re 1 each, subject to approval of the shareholders. <br /><br /> Shares of the company ended 4.28 per cent up at Rs 1,051.90 apiece on the BSE.<br /><br /><b>SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank"></a></b><br /><br /> <b><a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank">Motorola Edge 50 Fusion vs OnePlus Nord CE 4 – price, specs and features compared</a><a href="https://www.businessinsider.in/india/news/average-housing-prices-up-10-in-jan-mar-across-the-top-eight-cities/articleshow/110181627.cms" target="_blank"></a></b><br /><br /> <b><a href="https://www.businessinsider.in/india/news/average-housing-prices-up-10-in-jan-mar-across-the-top-eight-cities/articleshow/110181627.cms" target="_blank">Average housing prices up 10% in Jan-Mar across the top eight cities</a><a href="https://www.businessinsider.in/tech/mobile/news/motorola-edge-50-fusion-with-144hz-poled-display-500mah-battery-launched-starting-at-22999/articleshow/110170762.cms" target="_blank"></a></b><br /><br /> <b><a href="https://www.businessinsider.in/tech/mobile/news/motorola-edge-50-fusion-with-144hz-poled-display-500mah-battery-launched-starting-at-22999/articleshow/110170762.cms" target="_blank">Motorola Edge 50 Fusion with 144Hz pOLED display, 5,00mAh battery launched starting at ₹22,999</a></b><br />

Zydus Q4 net profit surges 4-fold to ₹1,182 cr; revenue at ₹5,534 cr

New Delhi, <keyword id="13247465" type="General" weightage="20" keywordseo="Zydus-Lifesciences" source="Orion">Zydus Lifesciences</keyword> Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 1,086.9 crore for the first quarter ended June 30, 2023 driven by strong sales growth from US formulations. The company had posted a net profit of Rs 518.3 crore for the same quarter last fiscal, Zydus Lifesciences said in a regulatory filing. <br /><br /> Revenue from operations during the quarter under review stood at Rs 5,139.6 crore as against Rs 3,964.4 crore in the year-ago period, up 29.6 per cent. <br /><br /> India geography clocked sales of Rs 1,920.6 crore in the first quarter as compared to Rs 1,816.7 crore in the corresponding period a year ago. <br /><br /> Sales from US formulations were at Rs 2,454.1 crore as compared to Rs 1,559.2 crore in the same quarter a year ago, up 57.4 per cent, the company said. <br /><br /> Active pharmaceutical ingredients clocked sales of Rs 138.9 crore in the first quarter as against Rs 122.4 crore in the corresponding quarter last fiscal, it added. <br /><br /> During the quarter, the company witnessed a broad-based operational growth in its key businesses and a favourable product mix enhanced profitability, Zydus Lifesciences Managing Director Sharvil Patel said. <br /><br /> "Strong execution and volume offtake drove revenue ramp-up in the US, while the India branded formulations business, adjusting for NLEM (national list of essential medicines) impact delivered solid 12 per cent growth," he added. <br /><br /> On the outlook, he said,"We remain reassured on achieving profitable growth aspirations for the fiscal year and thereby enhance stakeholder value."

Zydus Lifesciences Q1 2023-24 profit up 2-fold at Rs 1,087 cr

<ul><li><keyword id="4764339" type="General" weightage="20" keywordseo="drug-shortages" source="Orion">Drug shortages</keyword>, channel realignment and woes of competitors to aid US business of <keyword id="58106" type="General" weightage="20" keywordseo="indian-pharma" source="Orion">Indian pharma</keyword> cos.</li><li>Dr Reddy’s, Cipla, Zydus and Sun Pharmaceuticals gained from sales of generic cancer drugs in the US.</li><li>US FDA inspections are in full swing and the accelerating pace of new launches will improve outlook for US business in FY24, say analysts. </li></ul>The Indian pharma sector has gone through many ups and downs in the last few years – like falling from a Covid-high last year, adding to pricing pressures in its most important market. In the first quarter of FY24 however some of the US market pricing pressures are easing, making up for the slump in domestic sales. <br /><br />“Q1 FY24 turned out to be a tale of two divergent performances as US delivered across the board beat while domestic business, specifically acute, saw weakness in June. Price erosion came in at high single digit in US versus mid-teens last year reflecting in better US revenue growth and profitability,” said a report by YES Securities. <br /><br />Drug shortages, channel realignment and financial as well as regulatory woes of competitors seems to have helped curb US market price erosion in Q1 on a quarter-on-quarter, say analysts. <br /><br />The US market has been dented in the last few years for many reasons including pricing pressures — like supply chain disruptions, and a massive delay in approval of Abbreviated New Drug Applications (ANDAs) leading to fewer generic launches in the US. <br /><br />However, the ability to launch the generic version of a cancer drug gRevlimid in the US abated some of the concerns. Dr Reddy’s generated sales to the tune of $125 million from this generic in Q1 while Cipla, Zydus and Sun Pharmaceuticals reported gRevlimid sales between 40-60 million. <br /><br />“We believe the earnings support from gRevlimid is expected to drive the US base business and abate pricing pressure for the coming two years. Moreover, US FDA inspections are in full swing and the accelerating pace of new launches will improve outlook for US business in FY24,” J M Financial. <br /><br />Lupin and Zydus Life benefitted from exclusive launches of gSuprep and gTrokendi. Darunavir and gSpiriva are other drugs in the pipeline that can boost North America sales of Indian pharma companies.<br /><br /><table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;" class="redcator-table-advance"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"><strong>Stock <br /><br /></strong></td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;"><strong>Growth levers ahead</strong><br /><br /></td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Sun Pharma<br /><br /></td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Specialty performance <br /><br /></td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Dr Reddys<br /><br /></td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Revlimid contribution to sustain in 2Q<br /><br /></td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Zydus Lifesciences<br /><br /></td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Near-term US outlook promising<br /><br /></td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Cipla <br /><br /></td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">US base biz at $210- 215 mn hereon: mgmt<br /><br /></td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Lupin<br /><br /></td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Attractive launch pipeline<br /><br /></td></tr></tbody><tbody></tbody><tbody></tbody></table><em>Source: J M Financial</em><br /><br /><strong>Sun shines in the <keyword id="6382118" type="General" weightage="20" keywordseo="domestic-market" source="Orion">domestic market</keyword></strong> <br /><br />The domestic <keyword id="101756" type="General" weightage="20" keywordseo="pharma-market" source="Orion">pharma market</keyword> seems to see the after-effects of a delayed monsoon, which led to weakness in acute therapies like gastroenteritis which aids seasonal sales in Q1. This trend impacted key players like Dr Reddy’s, JB Chemicals and Alkem. <br /><br />Alkem however said that there has been no change in domestic sales even in July, August is expected to provide some quality on the same. <br /><br />Sun Pharma, however, is an outlier with a good performance in the domestic business as it boosted its sales strength along with new launches. It launched 105 new products in FY23 as compared to 77 new launches the year before. <br /><br />“Sun’s India business has grown at 11% compounded annual growth rate (CAGR) over FY20-23, driven by volume, price and new launches. We expect Sun’s India business to grow at around 10% CAGR over FY23-26,” said a report by IIFL Securities.<br /><br />  <div type="javascript" title="Custom" contenttype="Text"><cdata><![CDATA[]]></cdata></div><br />

US outlook improves for Indian pharma but domestic market under the cloud

<div style="float: right; margin: 15px 0 20px 20px;"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><a href="https://static-ssl.businessinsider.com/category/chart-of-the-day"> </a></td></tr><tr><td><a href="http://www.businessinsider.com/category/chart-of-the-day"></a></td><td><a href="http://www.businessinsider.com/verizon-buy-charter-most-subscribers-chart-2017-1"></a></td></tr></tbody></table></div><p>Alphabet <a href="http://www.businessinsider.com/alphabet-reports-q4-2016-earnings-2017-1" target="_blank">reported its Q4 2016 earnings</a> on Thursday, and the results were mixed: The company brought in more revenue than expected, but profits fell short, and its stock has taken a slight dip as a result.</p><p>The most interesting story at the company formerly known as Google is the fate of its "Other Bets" category - the projects that lie outside of the company's core businesses of Google search and advertising, like its Nest smart home products, Fiber internet service, and <a href="http://www.businessinsider.com/alphabets-verily-life-sciences-takes-800-million-investment-2017-1" target="_blank">Verily life-sciences unit</a>.</p><p>Alphabet <a href="http://www.businessinsider.com/alphabet-fourth-quarter-earnings-preview-2017-1" target="_blank">has put these bets</a> under <a href="http://www.businessinsider.com/alphabet-executive-departures-2016-10" target="_blank">increased scrutiny</a> in the last year, and the thinning-down seems to have had an effect. On Thursday, Alphabet said the category made $262 million in revenue, a 74% increase from the year-ago quarter. Its operating loss was lower, too.</p><p>However, as this chart from <a href="http://statista.com" target="_blank">Statista</a> shows, it's hard to call them successful. Though the other bets' losses have gone down recently, they still burned more than $3.6 billion over the course of 2016. Just in case there was any doubt, Alphabet is a search and advertising company through and through.</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Statista</span></p></div><p></p></div></div></p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/parents-unsuccessful-kids-have-common-science-2017-1">Science says parents of unsuccessful kids could have these 6 things in common</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="0ybG5hNDE65aZYRozOcOf8yh-IA1zS_5" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

You Searched For "Zydus Lifesciences profit and loss" and got 6 results

Zydus Q4 net profit surges 4-fold to ₹1,182 cr; revenue at ₹5,534 cr

PTI

Zydus Lifesciences Q1 2023-24 profit up 2-fold at Rs 1,087 cr

PTI

US outlook improves for Indian pharma but domestic market under the cloud

Katya Naidu

Alphabet's 'other bets' are bringing in more money, but still cost tons

Jeff Dunn

Google is going through a slow-motion employee revolt and its cofounders are missing in action

Nick Bastone

America is telling the Fed that the economy keeps improving

Akin Oyedele

Popular Keywords

Buying Guides